Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 171

1.

In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer.

Zagorac I, Fernandez-Gaitero S, Penning R, Post H, Bueno MJ, Mouron S, Manso L, Morente MM, Alonso S, Serra V, Muñoz J, Gómez-López G, Lopez-Acosta JF, Jimenez-Renard V, Gris-Oliver A, Al-Shahrour F, Piñeiro-Yañez E, Montoya-Suarez JL, Apala JV, Moreno-Torres A, Colomer R, Dopazo A, Heck AJR, Altelaar M, Quintela-Fandino M.

Nat Commun. 2018 Aug 29;9(1):3501. doi: 10.1038/s41467-018-05742-z.

2.

Skeletal muscle and solitary bone metastases from malignant melanoma: multimodality imaging and oncological outcome.

Gómez-León N, Pacheco-Barcia V, Ballesteros AI, Fraga J, Colomer R, Friera A.

Melanoma Res. 2018 Jul 2. doi: 10.1097/CMR.0000000000000466. [Epub ahead of print]

PMID:
29975212
3.

Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Colomer R, Aranda-López I, Albanell J, García-Caballero T, Ciruelos E, López-García MÁ, Cortés J, Rojo F, Martín M, Palacios-Calvo J.

Clin Transl Oncol. 2018 Jun 18. doi: 10.1007/s12094-018-1909-1. [Epub ahead of print]

PMID:
29916189
4.

Nivolumab-induced thyroid dysfunction in patients with lung cancer.

Ramos-Levi AM, Rogado J, Sanchez-Torres JM, Colomer R, Marazuela M.

Endocrinol Diabetes Nutr. 2018 Jun 14. pii: S2530-0164(18)30109-5. doi: 10.1016/j.endinu.2018.05.005. [Epub ahead of print] English, Spanish.

PMID:
29910159
5.

[Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology].

Palacios Calvo J, Albanell J, Rojo F, Ciruelos E, Aranda-López I, Cortés J, García-Caballero T, Martín M, López-García MÁ, Colomer R.

Rev Esp Patol. 2018 Apr - Jun;51(2):97-109. doi: 10.1016/j.patol.2017.12.002. Epub 2018 Mar 14. Spanish.

PMID:
29602380
6.

Predictors of unknown cancer in patients with ischemic stroke.

Quintas S, Rogado J, Gullón P, Pacheco-Barcia V, Dotor García-Soto J, Reig-Roselló G, Mondéjar R, Colomer R, Vivancos J.

J Neurooncol. 2018 May;137(3):551-557. doi: 10.1007/s11060-017-2741-0. Epub 2018 Jan 8.

PMID:
29313183
7.

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Colomer R, Aranda-López I, Albanell J, García-Caballero T, Ciruelos E, López-García MÁ, Cortés J, Rojo F, Martín M, Palacios-Calvo J.

Clin Transl Oncol. 2018 Jul;20(7):815-826. doi: 10.1007/s12094-017-1800-5. Epub 2017 Dec 22. Erratum in: Clin Transl Oncol. 2018 Jun 18;:.

8.

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.

Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Kiermaier A, Eng-Wong J, Dang C; BERENICE Study Group.

Ann Oncol. 2018 Mar 1;29(3):646-653. doi: 10.1093/annonc/mdx773.

9.

Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC.

Colomer R, Hall P, Szkultecka-Debek M, Bondi RC, Flinois A, Auziere S, Le Cléac'h JY.

Breast Cancer Res Treat. 2018 Feb;168(1):197-205. doi: 10.1007/s10549-017-4567-z. Epub 2017 Nov 23.

10.

Critically short telomeres and toxicity of chemotherapy in early breast cancer.

Quintela-Fandino M, Soberon N, Lluch A, Manso L, Calvo I, Cortes J, Moreno-Antón F, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Mouron S, Guerra J, Bermejo B, Zamora E, García-Saenz JA, Simon SP, Carrasco E, Escudero MJ, Campo R, Colomer R, Blasco MA.

Oncotarget. 2017 Mar 28;8(13):21472-21482. doi: 10.18632/oncotarget.15592.

11.

Strategies to design clinical studies to identify predictive biomarkers in cancer research.

Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I.

Cancer Treat Rev. 2017 Feb;53:79-97. doi: 10.1016/j.ctrv.2016.12.005. Epub 2016 Dec 30. Review.

12.

Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells.

Wagner R, Stübiger G, Veigel D, Wuczkowski M, Lanzerstorfer P, Weghuber J, Karteris E, Nowikovsky K, Wilfinger-Lutz N, Singer CF, Colomer R, Benhamú B, López-Rodríguez ML, Valent P, Grunt TW.

Oncotarget. 2017 Feb 14;8(7):11600-11613. doi: 10.18632/oncotarget.14591.

13.

18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial.

Quintela-Fandino M, Lluch A, Manso L, Calvo I, Cortes J, García-Saenz JA, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Guerra J, Bermejo B, Zamora E, Moreno-Anton F, Pernas Simon S, Carrato A, Lopez-Alonso A, Escudero MJ, Campo R, Carrasco E, Palacios J, Mulero F, Colomer R.

Clin Cancer Res. 2017 Mar 15;23(6):1432-1441. doi: 10.1158/1078-0432.CCR-16-0738. Epub 2016 Sep 1.

14.

Advanced breast cancer clinical nursing curriculum: review and recommendations.

Vila C, Reñones C, Ferro T, Peñuelas MÁ, Del Mar Jiménez M, Rodríguez-Lescure Á, Muñoz M, Colomer R.

Clin Transl Oncol. 2017 Feb;19(2):251-260. doi: 10.1007/s12094-016-1530-0. Epub 2016 Aug 3. Review.

15.

Is Metastatic Disease the Best Setting for Cost-Effectiveness Studies?

Colomer R, Pascual T, Albanell J.

J Clin Oncol. 2016 Sep 10;34(26):3226-7. doi: 10.1200/JCO.2016.68.2534. Epub 2016 Jul 18. No abstract available.

PMID:
27432928
16.

Antiangiogenics and Hypoxic Response: Role of Fatty Acid Synthase Inhibitors.

Bueno MJ, Sanchez J, Colomer R, Quintela-Fandino M.

Curr Drug Targets. 2016;17(15):1735-1746. Review.

PMID:
27138758
17.

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.

Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, Lee SC, Mehta AO, Kim SB, Bachelot T, Goswami C, Deo S, Bose R, Wong A, Xu F, Yao B, Bryce R, Carey LA.

JAMA Oncol. 2016 Dec 1;2(12):1557-1564. doi: 10.1001/jamaoncol.2016.0237.

PMID:
27078022
18.

Dermatofibrosarcoma Protu-Berans with Lung Metastasis Requiring Pneumonectomy.

Collazo Lorduy A, Obispo B, Villar K, Buchser D, Rogado J, de la Maza MD, Alfranca YL, Colomer R.

Rare Tumors. 2015 Dec 29;7(4):5981. doi: 10.4081/rt.2015.5981. eCollection 2015 Dec 29.

19.

Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents.

Colomer R, Sarrats A, Lupu R, Puig T.

Curr Drug Targets. 2017;18(2):147-159. doi: 10.2174/1389450117666160112113930. Review.

PMID:
26758667
20.

A Fatty Acid Synthase Inhibitor Shows New Anticancer Mechanisms.

Bueno MJ, Colomer R.

EBioMedicine. 2015 Aug;2(8):778-779. doi: 10.1016/j.ebiom.2015.08.023. Epub 2015 Aug 14. No abstract available.

Supplemental Content

Loading ...
Support Center